NASDAQ:BEAM Beam Therapeutics Q2 2026 Earnings Report $25.67 +1.17 (+4.78%) Closing price 04:00 PM EasternExtended Trading$25.50 -0.17 (-0.64%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Beam Therapeutics EPS ResultsActual EPS-$1.18Consensus EPS -$1.11Beat/MissMissed by -$0.07One Year Ago EPS-$1.00Beam Therapeutics Revenue ResultsActual Revenue$0.49 millionExpected Revenue$16.37 millionBeat/MissMissed by -$15.88 millionYoY Revenue Growth-94.20%Beam Therapeutics Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateTuesday, August 4, 2026Conference Call Time7:00AM ETUpcoming EarningsBeam Therapeutics' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, November 4, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Beam Therapeutics Earnings HeadlinesBeam Therapeutics consensus price target decreased by 13.38% to MX$839.72October 4 at 6:14 AM | msn.comBeam Therapeutics (NASDAQ:BEAM) Raised to Sell at Wall Street ZenOctober 3 at 1:07 AM | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 5 at 1:00 AM | Banyan Hill Publishing (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMOctober 1, 2026 | prnewswire.comBeam alleges Chinese biotech, and its U.S. partner Serapha stole trade secretsSeptember 30, 2026 | seekingalpha.comWill IP Theft Allegations Against YolTech and Serapha Bio Change Beam Therapeutics' (BEAM) NarrativeSeptember 30, 2026 | finance.yahoo.comSee More Beam Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Beam Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Beam Therapeutics and other key companies, straight to your email. Email Address About Beam TherapeuticsBeam Therapeutics (NASDAQ:BEAM) is a biotechnology company developing precision genetic medicines using base editing, a technology designed to make targeted changes to DNA without cutting both strands of the DNA double helix. The company’s platform is intended to address diseases caused by specific genetic mutations and to support the development of potentially durable treatments. Beam’s research and development activities focus on areas including hematology, liver diseases and genetic disorders. Its pipeline has included investigational programs such as BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency and BEAM-301 for glycogen storage disease type Ia. These programs are investigational and remain subject to clinical and regulatory evaluation. Founded in 2017 and headquartered in Cambridge, Massachusetts, Beam was established by scientists and entrepreneurs including David Liu, a pioneer in base-editing technology. John Evans has served as the company’s chief executive officer. Beam’s operations are centered on advancing its proprietary editing platform and developing genetic medicines for patients with serious diseases.View Beam Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles NVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street DividedMcCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last Longer Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
